Shenzhen New Industries Biomedical (300832) — Cash Flow-to-Debt Ratio
Shenzhen New Industries Biomedical (300832) has a Cash Flow-to-Debt Ratio of 0.73x as of September 2025, meaning its operating cash flow of CN¥606.21 Million could theoretically repay 1% of its total liabilities (CN¥831.98 Million) in one year. See 300832 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Shenzhen New Industries Biomedical Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Shenzhen New Industries Biomedical across 13 annual periods. For the full cash flow conversion analysis, see Shenzhen New Industries Biomedical cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for Shenzhen New Industries Biomedical (2012–2024)
Year-by-year debt coverage analysis for Shenzhen New Industries Biomedical. Check Shenzhen New Industries Biomedical cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 1.30x | CN¥1.36 Billion | CN¥1.04 Billion | ▼ -37.8% |
| 2023 | 2.09x | CN¥1.42 Billion | CN¥678.09 Million | ▲ +33.7% |
| 2022 | 1.56x | CN¥962.39 Million | CN¥615.06 Million | ▲ +5.9% |
| 2021 | 1.48x | CN¥773.22 Million | CN¥523.51 Million | ▼ -24.2% |
| 2020 | 1.95x | CN¥976.65 Million | CN¥501.49 Million | ▼ -25.3% |
| 2019 | 2.61x | CN¥831.73 Million | CN¥318.92 Million | ▲ +2.0% |
| 2018 | 2.56x | CN¥701.97 Million | CN¥274.52 Million | ▲ +21.8% |
| 2017 | 2.10x | CN¥524.73 Million | CN¥250.00 Million | ▼ -19.9% |
| 2016 | 2.62x | CN¥486.81 Million | CN¥185.75 Million | ▲ +7.0% |
| 2015 | 2.45x | CN¥305.93 Million | CN¥124.94 Million | ▲ +30.3% |
| 2014 | 1.88x | CN¥253.47 Million | CN¥134.92 Million | ▲ +120.2% |
| 2013 | 0.85x | CN¥138.33 Million | CN¥162.12 Million | ▼ -0.7% |
| 2012 | 0.86x | CN¥55.80 Million | CN¥64.93 Million | — |